Recombinant activated coagulation factor VII (rFVIIa) is known to be effective in the management of acquired deficiencies of factor VII and platelet function defects. But recently, rFVIIa has been successfully used to treat ongoing bleeding in disseminated intravascular coagulopathy (DIC) condition. The patient reported here was suspected to be suffering from toxic hepatitis on admission. After percutaneous liver biopsy, bleeding occurred and did not stop even after right hepatic artery embolization. The patient developed a severe hemorrhage that resulted in hypovolemic shock, hemoperitoneum, and a massive subcapsular hematoma. The patient then developed DIC due to massive transfusion, as well as acute liver necrosis. The patient was given ...
Recombinant activated factor VII (rFVIIa) is an hemostatic agent that was originally developed for t...
Recombinant factor VIIa (rFVIIa) was developed for the treatment of bleeding in hemophilic patients ...
Objectives: To describe the effects of recombinant activated factor VII (rFVIIa) in the treatment ...
Recombinant activated factor VII, a bypassing hemostatic agent originally developed for the treatmen...
Recombinant activated factor VII (rFVIIa) has been used in the treatment of various congenital and a...
PubMedID: 18838398The literature on the use of recombinant factor VIIa (rFVIIa), which was initially...
WOS: 000255989700005PubMed ID: 18484474Coagulopathy is an important cause of mortality in critically...
factor VII (rFVIIa) was approved for treatment of hemorrhages in patients with hemophilia who develo...
Recombinant human factor VIIa (rFVIIa) is approved by the US Food and Drug Administration for use in...
Recombinant activated factor VII (rFVIIa) has been successfully used ''off-label'' in patients with ...
Hemorrhage in patients with hematologic malignancies is often difficult to manage as many of these p...
AbstractObjectiveRecombinant activated factor VII (rFVIIa) is a novel hemostatic agent originally de...
The paper describe the use of rFVIIa in the management of massive bleeding in a patient with polytra...
Recombinant activated factor VII (rFVIIa) has been suc- cessfully used \u2018\u2018off-label\u2019\...
Abstract Background Recently, there has been an increased use of recombinant activated factor VII (r...
Recombinant activated factor VII (rFVIIa) is an hemostatic agent that was originally developed for t...
Recombinant factor VIIa (rFVIIa) was developed for the treatment of bleeding in hemophilic patients ...
Objectives: To describe the effects of recombinant activated factor VII (rFVIIa) in the treatment ...
Recombinant activated factor VII, a bypassing hemostatic agent originally developed for the treatmen...
Recombinant activated factor VII (rFVIIa) has been used in the treatment of various congenital and a...
PubMedID: 18838398The literature on the use of recombinant factor VIIa (rFVIIa), which was initially...
WOS: 000255989700005PubMed ID: 18484474Coagulopathy is an important cause of mortality in critically...
factor VII (rFVIIa) was approved for treatment of hemorrhages in patients with hemophilia who develo...
Recombinant human factor VIIa (rFVIIa) is approved by the US Food and Drug Administration for use in...
Recombinant activated factor VII (rFVIIa) has been successfully used ''off-label'' in patients with ...
Hemorrhage in patients with hematologic malignancies is often difficult to manage as many of these p...
AbstractObjectiveRecombinant activated factor VII (rFVIIa) is a novel hemostatic agent originally de...
The paper describe the use of rFVIIa in the management of massive bleeding in a patient with polytra...
Recombinant activated factor VII (rFVIIa) has been suc- cessfully used \u2018\u2018off-label\u2019\...
Abstract Background Recently, there has been an increased use of recombinant activated factor VII (r...
Recombinant activated factor VII (rFVIIa) is an hemostatic agent that was originally developed for t...
Recombinant factor VIIa (rFVIIa) was developed for the treatment of bleeding in hemophilic patients ...
Objectives: To describe the effects of recombinant activated factor VII (rFVIIa) in the treatment ...